To the Editor:
The Technical Brief by Hawkins (1 ) refers to the increase in measured serum free thyroxine (FT 4 ) concentrations by furosemide as "interference", and this deserves comment. As discussed previously (2, 3 ) , one can legitimately conclude that an assay is unaffected after the addition of exogenous substances (such as thyroid hormone-binding proteins or binding inhibitors) if the assay measures the total amount of the analyte (such as T 4 ). The situation is, however, different with assays measuring free analyte (e.g., FT 4 ) concentrations. This is because the FT 4 concentration (as dictated by the law of mass action) depends on the equilibrium that exists between the protein-bound T 4 (PBT 4 ) and the serum binding capacity (sBC, which is defined as the concentration of free binding sites times their binding affinity toward T 4 ):
One can readily predict from this equation that drugs such as furosemide, which bind to the thyroid hormone-binding sites (4, 5 ) , will cause an increase in the FT 4 concentration by reducing the available binding sites (sBC). This effect will be observed irrespective of whether the drug is a true component of the sample or is a contaminant. Hence, the rise in FT 4 concentration observed by Hawkins (1 ) is to be expected by theory and is not the result of assay interference.
It is evident from the data, however, that the degree of response to furosemide depends on the methodology used. The differences in FT 4 methods could be related, as Hawkins suggests, to differences in serum dilution in these assays. Increasing the serum dilution in a FT 4 assay, especially in an assay containing T 4 -binding substances (e.g., bovine serum albumin), will greatly disturb the endogenous T 4 /protein equilibrium and will lead to underestimation of FT 4 in sera whose T 4 binding capacities are reduced (3 ). Thus, assays having the highest serum dilution will be expected to show the largest deviation from the true FT 4 concentration.
Clearly the statement (1 ) that clinician awareness of the effect of drugs on FT 4 (and other analytes) is of paramount importance. Equally important is the knowledge that the effects of drugs are transient and will persist only as long as sufficiently high concentrations of drug remain in the circulation. For example, in the case of furosemide, it has been documented (6 ) that regardless the route of administration, 69 -97% of the furosemide is removed from the bloodstream in the first 4 h after the drug is given. If a sufficient time period is allowed between drug administration and venipuncture, the effect of the drug on FT 4 estimation will be eliminated or greatly diminished.
In summary, furosemide and other drugs capable of binding to the thyroid hormone-binding proteins (e.g., ketoprofen, phenylbutazone, mefenamic acid, phenytoin, probenecid, sulindac, and fenclofenac) should increase the measured FT 4 concentration in assays that truly measure FT 4 , i.e., the resulting increase in FT 4 concentration is not caused by interference. The magnitude of the FT 4 increase varies with the FT 4 assay being used. The variability is likely the result of differences in the degree of disturbance of the endogenous T 4 /protein equilibrium exerted by the assay reagents. Assays that cause the least disturbance in this equilibrium will best reflect the true FT 4 values. 
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